Sarepta Therapeutics

Commercial-stage biopharma company focused on the discovery & development of precision genetic medicine to treat rare neuromuscular diseases.

[Sarepta Therapeutics @Sarepta]

We’re at the 2026 ASGCT Annual Meeting in Boston, sharing updates with peers across the gene and cell therapy field. #ASGCT

[Sarepta Therapeutics @Sarepta]

Today we provided an update on financial results. Our CEO on Sarepta’s position:

[Sarepta Therapeutics @Sarepta]

Today we released our financial results for Q1 2026 and provided an update on clinical development programs. Read more at our website.

[Sarepta Therapeutics @Sarepta]

Today we announced early clinical results from Phase 1/2 ascending-dose studies of SRP-1001 for FSHD1 and SRP-1003 for DM1. The results demonstrated dose-dependent muscle exposure, early biomarker effects and favorable tolerability, reinforcing confidence in the potential for differentiated delivery capabilities of our platform. Learn more: https://t.co/PGXyrSg0ju

[Sarepta Therapeutics @Sarepta]

On Wednesday, March 25 at 8:30 am Eastern, we will host a live webcast to discuss first clinical results from two of our siRNA programs for neuromuscular diseases. Tune in here: https://t.co/f4v5lc6rqd

[Sarepta Therapeutics @Sarepta]

News: Today we shared an update on our ongoing interactions with the U.S. FDA and intention to submit sNDAs seeking conversion of accelerated approvals to traditional approvals by the end of April. Visit our website for more information.

[Sarepta Therapeutics @Sarepta]

Happy to be here in Orlando at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference sharing updates and connecting with the community. Come find us! #MDAconference #MDA

[Sarepta Therapeutics @Sarepta]

@OmarAbb56696664 Hello, Omar. If you have questions, it's best to speak directly with your healthcare provider. You also can email our Patient Affairs team at [email protected]. Thank you!

[Sarepta Therapeutics @Sarepta]

Excited to be a partner of the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. We’ll be there sharing updates on how Sarepta is advancing science and generating new insights for patients and healthcare providers. #MDAconference

[Sarepta Therapeutics @Sarepta]

Today, we released our financial results for Q4 and the full year of 2025. Our CEO on the results:

[Sarepta Therapeutics @Sarepta]

@DhandaBihari Hello, and thank you for your message. Please contact your healthcare provider to discuss medical questions. If you have additional questions, you can email our Patient Affairs team at [email protected]. Thank you.

[Sarepta Therapeutics @Sarepta]

Today we announced positive topline three-year EMBARK results showing that our approved gene therapy significantly slows disease progression on key functional measures in ambulatory Duchenne patients. Read the release at https://t.co/Fj9GrqIHK8.

[Sarepta Therapeutics @Sarepta]

Today at #JPM26, CEO Doug Ingram discussed our preliminary Q4 and full-year 2025 performance and shared an update on corporate developments. Read more: https://t.co/NLgt8z91sK

[Sarepta Therapeutics @Sarepta]

We just announced our preliminary fourth quarter and full-year 2025 net product revenues. Read more: https://t.co/NLgt8z9zii

[Sarepta Therapeutics @Sarepta]

Sarepta announced the submission of its CTA for Study SRP-1005-101 to the New Zealand Medicines and Medical Devices Safety Authority. SRP-1005 is an investigational small interfering RNA (siRNA) therapeutic for the treatment of Huntington’s Disease. Read more: https://t.co/KagZn0KIGY

[Sarepta Therapeutics @Sarepta]

Big news: Duchenne muscular dystrophy is now on the Recommended Uniform Screening Panel (RUSP)! This milestone reflects tireless advocacy from families, organizations and leaders committed to early diagnosis. Learn more: https://t.co/n0bLxnS884
#Newbornscreening

[Sarepta Therapeutics @Sarepta]

We just announced that the U.S. FDA approved to begin dosing in Cohort 8 of the ENDEAVOR study to evaluate the use of an enhanced immunosuppressive regimen as part of treatment with our gene therapy for non-ambulatory patients. Read the press release: https://t.co/8h4x7YX4dZ

[Sarepta Therapeutics @Sarepta]

@WaleedWali19 Hello Waleed, and thank you for your message. Please contact your healthcare provider to discuss medical questions. If you have additional questions, you can email our Patient Affairs team at [email protected]. Thank you!

[Sarepta Therapeutics @Sarepta]

Today we shared an update on the prescribing information for our approved gene therapy. Read the press release: https://t.co/jclQqXfk54

For U.S. residents